Microvolt T-wave alternans as a predictor of mortality and severe arrhythmias in patients with left-ventricular

Charlotte J van der Avoort1, Kristian B Filion, Nandini Dendukuri

  • 1Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada. charlotte.vanderavoort@gmail.com

Insights

Microvolt T-wave alternans (MTWA) can help identify patients with severe left ventricular dysfunction at higher risk for mortality or arrhythmias. Further research is needed to fully define its clinical utility in guiding implantable cardioverter defibrillator decisions.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Medical Diagnostics

Background:

  • Implantable cardioverter defibrillators (ICDs) are effective for primary prevention of arrhythmic events.
  • High costs necessitate identifying patients who benefit most from ICDs.
  • Microvolt T-wave alternans (MTWA) is a potential tool for patient stratification.

Purpose of the Study:

  • To evaluate MTWA as a predictor of mortality and severe arrhythmic events in patients with severe left-ventricular dysfunction.
  • To synthesize evidence from randomized controlled trials and prospective cohort studies.

Main Methods:

  • Systematic literature search of multiple databases (MEDLINE, EMBASE, etc.) from January 1990 to May 2007.
  • Inclusion of primary prevention randomized controlled trials and prospective cohort studies with ≥12 months follow-up.
  • Bayesian hierarchical models used for data synthesis.

Main Results:

  • Analysis of 8 cohort studies with 1,946 patients; no trials identified.
  • Positive MTWA test results were associated with a higher risk of mortality or severe arrhythmic events (RR = 2.7, 95% CrI = 1.4, 6.1).
  • Similar findings observed when comparing non-negative MTWA results to negative results.

Conclusions:

  • A positive MTWA test predicts adverse outcomes in severe left ventricular dysfunction.
  • The clinical utility of MTWA is incompletely defined due to a wide credible interval.
  • High-quality studies are needed to refine MTWA's role in ICD implantation decisions.
Abstract

Related Concept Videos

Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
Dysrhythmias V: Evaluating Dysrhythmias01:30

Dysrhythmias V: Evaluating Dysrhythmias

Dysrhythmias, also known as arrhythmias, are disturbances in the heart's rhythm that range from benign to life-threatening. A thorough evaluation is crucial for appropriate management and involves a comprehensive medical history, physical examination, and various diagnostic tests.Medical HistorySymptoms: Collect detailed information on palpitations, dizziness, syncope, chest pain, and fatigue. Note their onset, frequency, and triggers.Previous Cardiac Issues: Document any history of heart...
Mitral Regurgitation II: Clinical Features and Diagnostic Tests01:23

Mitral Regurgitation II: Clinical Features and Diagnostic Tests

Mitral regurgitation (MR) is a valvular heart disorder in which the mitral valve fails to close tightly, allowing blood to leak backward into the heart. Understanding the clinical manifestations, assessment, diagnostic findings, and medical management of MR is crucial to effectively managing affected patients.Clinical Manifestations of Mitral RegurgitationMitral regurgitation can be acute or chronic, each presenting differently and requiring different approaches:1. Acute Mitral...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Dysrhythmias II: Classification of Tachyarrhythmias01:28

Dysrhythmias II: Classification of Tachyarrhythmias

Tachyarrhythmias are a type of dysrhythmia where the heart rate exceeds 100 beats per minute. Here are some common types of tachyarrhythmias:Sinus TachycardiaSinus tachycardia originates from increased impulses from the sinus node, leading to an elevated heart rate. It is often triggered by stress, fever, or exercise.Patients may experience palpitations, a sensation of a racing heart, dizziness, and chest discomfort.Causes and Risk Factors: Common causes include physical exertion, emotional...